| Trial ID: | L4076 |
| Source ID: | NCT02783196
|
| Associated Drug: |
Liraglutide
|
| Title: |
Effect of Liraglutide on Clock Genes
|
| Acronym: |
LIR-CG
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Liraglutide|DRUG: Placebo
|
| Outcome Measures: |
Primary: Clock Gene expression, The Clock Genes mRNA expression will be assessed in white blood cells, Up to 95 days | Secondary: AMPK mRNA expression, he AMPK mRNA expression will be assessed in white blood cells on day 0, on day 40 and on day 95, Up to 95 days|SIRT1 mRNA expression, SIRT1 mRNA expression will be assessed in white blood cells on day 0, on day 40 and on day 95, Up to 95 days|Beta-cell function, Beta-cell function based on oral glucose tolerance test (OGTT) will be assessed on day -3, on day 37 and on day 92, Up to 92 days|Overall glycemia, Overall glycemia assessed with continuous glucose monitoring system (CGMS) will be performed during 3 days at baseline from day - 3 to day 0, again from day 37 to 40 and three days before the end of intervention from day 92 to day 95, Up to 95 days
|
| Sponsor/Collaborators: |
Sponsor: Tel Aviv University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
14
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2016-07
|
| Completion Date: |
2017-06
|
| Results First Posted: |
|
| Last Update Posted: |
2016-05-26
|
| Locations: |
Diabetes Unit E. Wolfson Hospital, Holon, Tel Aviv, 58100, Israel
|
| URL: |
https://clinicaltrials.gov/show/NCT02783196
|
